New Innovations in Heart Failure

OSU Wexner Medical Center logo New Innovations in Heart Failure. Today We’ve invited two of Ohio State University’s cardiovascular experts to take us through the new therapies available to our heart failure patients and the practice changing guidelines to help us provide the best care to our patients. First, we have Heart Failure Cardiologist and Assistant Professor of Internal Medicine Dr Ajay Vallakati. Ajay specializes in Cardiac Amyloidosis. Second, we have Dr Indra Bole who is also an Assistant Professor of Internal Medicine and Heart Failure trained Cardiologist. His clinical interests are focused on cardiogenic shock, mechanical circulatory support, and heart transplant.

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to:

  • Discuss pharmacological management of heart failure
  • Recognize new heart failure therapies focusing on ivabradine, sacubitril-valsartan, and SGLT2i
  • Understand the benefit of SGTL2i in the population of patients with heart failure with reduced ejection fraction
  • Understand the benefit of SGTL2i in the population of patients with heart failure with preserved ejection fraction

You’ll also learn about the following:

  • Heart Failure Classification
  • Mortality
  • Goal Directed Medical Therapy
  • Advanced Therapies in Heart Failure

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.

Learn About Symptom Relief for Patients with Heart Failure

OSUWexnerbloglogo2014 Learn About Symptom Relief for Patients with Heart Failure. The American Lung Association has a slogan “When you can’t breathe, nothing else matters”. And that is particulary true for patients with end-stage cardiac disease. But the good news is that we have treatment approaches that can help and that is where palliative medicine comes in. I’m pleased to welcomes Associate Professor of Internal Medicine and palliative medicine specialist, Dr. Todd Barrett.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: REVIEW Palliative Care
Domains; and REVIEW Symptom Burden and Treatment in Heart Failure.

You’ll also learn about the following:

  • Heart conditions that benefit from palliative medicine
  • Opioid selection and strategies for use
  • Opioid side effects
  • Fluid management strategies to improve shortness of breath
  • SGLT2 inhibitors
  • Palliative care versus hospice care
  • Incorporating palliative care into usual cardiac care
  • COVID-19 related challenges in providing palliative care

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.

Learn About the Medical Management of Heart Failure on CME Webcast

OSUWexnerbloglogo2014 Learn About the Medical Management of Heart Failure on CME Webcast. Heart failure is an indiscriminate villain and can attack the rich and the poor, man or woman, old or young. But the good news is that we have better medical treatments for heart failure than ever before. On this CME Webcast, we’re going to update you about them. Joining our moderator in the studio are two heart failure cardiologists from the Ohio State University. Dr. Ajay Vallakati is an Assistant Professor and Dr. Brent Lampert is an Associate Professor, both from the Department of Internal Medicine.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: UNDERSTAND the mechanism of action and indications for sacubitril-valsartan; UNDERSTAND the mechanism of action and indications for ivabradine; DISCUSS the pharmacological management of heart failure; and RECOGNIZE new heart failure therapies including sacubitril-valsartan and ivabradine as well as understand their role in treating heart failure.

You’ll also learn about the following:

  • New medications to treat heart failure
  • Selecting an ACE inhibitor
  • Selecting a diuretic
  • Diastolic versus systolic heart failure treatment
  • Counseling patients about sodium and fluid intake
  • When to place an automatic implantable cardiac defibrillator
  • Follow-up testing of patients with heart failure

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.